We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Two companion papers out of Rutgers University — published June 14 in Nature Metabolism and Nature Communications—have traced ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...